Vaccinating chickens against avian influenza with fowlpox recombinants expressing the H7 haemagglutinin.
OBJECTIVE
To evaluate the vaccine efficacy of a fowlpox virus recombinant expressing the H7 haemagglutinin of avian influenza virus in poultry.


METHODS
Specific-pathogen-free poultry were vaccinated with fowlpox recombinants expressing H7 or H1 haemagglutinins of influenza virus. Chickens were vaccinated at 2 or 7 days of age and challenged with virulent Australian avian influenza virus at 10 and 21 days later, respectively. Morbidity and mortality, body weight change and the development of immune responses to influenza haemagglutinin and nucleoprotein were recorded.


RESULTS
Vaccination of poultry with fowlpox H7 avian influenza virus recombinants induced protective immune responses. All chickens vaccinated at 7 days of age and challenged 21 days later were protected from death. Few clinical signs of infection developed. In contrast, unvaccinated or chickens vaccinated with a non-recombinant fowlpox or a fowlpox expressing the H1 haemagglutinin of human influenza were highly susceptible to avian influenza. All those chickens died within 72 h of challenge. In younger chickens, vaccinated at 2 days of age and challenged 10 days later the protection was lower with 80% of chickens protected from death. Chickens surviving vaccination and challenge had high antibody responses to haemagglutinin and primary antibody responses to nucleoprotein suggesting that although vaccination protected substantially against disease it failed to completely prevent replication of the challenge avian influenza virus.


CONCLUSIONS
Vaccination of chickens with fowlpox virus expressing the avian influenza H7 haemagglutinin provided good protection against experimental challenge with virulent avian influenza of H7 type. Although eradication will remain the method of first choice for control of avian influenza, in the circumstances of a continuing and widespread outbreak the availability of vaccines based upon fowlpox recombinants provides an additional method for disease control.
Boyle
D B
DB
CSIRO, Division of Animal Health, Australian Animal Health Laboratory, Geelong, Victoria.
Selleck
P
P
Heine
H G
HG
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D005587:Fowlpox virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology; D009980:Influenza A virus / Q000235:genetics / Q000276:immunology*; D005585:Influenza in Birds / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013047:Specific Pathogen-Free Organisms; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D000914:Antibodies, Viral; D017931:DNA Primers; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D014614:Vaccines, Synthetic; D014765:Viral Vaccines